Brooklyn Enterprise Value over EBIT Trend from 2010 to 2022

BTX
 Stock
  

USD 0.51  0.04  7.27%   

Brooklyn Immunotherapeuti Enterprise Value over EBIT yearly trend continues to be fairly stable with very little volatility. Enterprise Value over EBIT will likely drop to -2.16 in 2022. During the period from 2010 to 2022, Brooklyn Immunotherapeuti Enterprise Value over EBIT regression line of anual values had r-squared of 0.06 and arithmetic mean of (1.24). Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.8 M) in 2022.
  
Check Brooklyn Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brooklyn main balance sheet or income statement drivers, such as Direct Expenses of 541.5 K, Cost of Revenue of 9.2 M or Gross Profit of 12.2 M, as well as many exotic indicators such as Long Term Debt to Equity of 3.0E-4, PPandE Turnover of 1.03 or Receivables Turnover of 11.02. Brooklyn financial statements analysis is a perfect complement when working with Brooklyn Immunotherapeuti Valuation or Volatility modules. It can also supplement Brooklyn Immunotherapeuti's financial leverage analysis and stock options assessment as well as various Brooklyn Immunotherapeuti Technical models . Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors.

Brooklyn Immunotherapeuti Quarterly Enterprise Value over EBIT

0.0

Brooklyn Enterprise Value over EBIT Breakdown

Showing smoothed Enterprise Value over EBIT of Brooklyn Immunotherapeutics with missing and latest data points interpolated. Measures the ratio between [EV] and [EBITUSD].Brooklyn Immunotherapeuti's Enterprise Value over EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brooklyn Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value over EBIT10 Years Trend
Increasing
Stable
   Enterprise Value over EBIT   
Share
       Timeline  

Brooklyn Enterprise Value over EBIT Regression Statistics

Arithmetic Mean(1.24)
Geometric Mean 7.11
Coefficient Of Variation(2,694)
Mean Deviation 16.07
Median(4.00)
Standard Deviation 33.48
Sample Variance 1,121
Range 147.00
R-Value 0.24
Mean Square Error 1,151
R-Squared 0.06
Significance 0.43
Slope 2.08
Total Sum of Squares 13,455

Brooklyn Enterprise Value over EBIT History

2012 -12.0
2013 -44.0
2014 -7.0
2015 -3.0
2016 -11.0
2017 -23.0
2018 103.0
2019 -6.0
2020 -1.0
2021 -2.0
2022 -2.16

Other Fundumenentals of Brooklyn Immunotherapeuti

About Brooklyn Immunotherapeuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brooklyn Immunotherapeuti income statement, its balance sheet, and the statement of cash flows. Brooklyn Immunotherapeuti investors use historical funamental indicators, such as Brooklyn Immunotherapeuti's Enterprise Value over EBIT, to determine how well the company is positioned to perform in the future. Although Brooklyn Immunotherapeuti investors may use each financial statement separately, they are all related. The changes in Brooklyn Immunotherapeuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brooklyn Immunotherapeuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brooklyn Immunotherapeuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brooklyn Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(1.60) (1.64) 
Enterprise Value195.9 M211.3 M
Tangible Asset Value29.5 M23.7 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-122 M-125.2 M
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Brooklyn Immunotherapeuti's public news can be used to forecast risks associated with investment in Brooklyn. The trend in average sentiment can be used to explain how an investor holding Brooklyn can time the market purely based on public headlines and social activities around Brooklyn Immunotherapeutics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Brooklyn Immunotherapeuti's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brooklyn Immunotherapeuti's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brooklyn Immunotherapeuti's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Brooklyn Immunotherapeuti.

Brooklyn Immunotherapeuti Implied Volatility

    
  0.0  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Moving together with Brooklyn Immunotherapeuti

0.71AGLEAeglea Biothera TrendingPairCorr

Moving against Brooklyn Immunotherapeuti

0.61ALLOAllogene Therapeutics Downward RallyPairCorr
The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
34.1 M
Return On Assets
-0.35
Return On Equity
-4.27
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.